The carbohydrate-deficient glycoprotein syndrome (CDGS) is a developmental disease associated with an abnormally high isoelectric point of serum transferrin. Carbohydrate analyses of this glycoprotein initially suggested a defect in N-linked oligosaccharide processing, although more recent studies indicate a defect in the attachment of these sugar chains to the protein. We studied both serum glycoproteins and fibroblast-derived [2-3H]mannose-labeled oligosaccharides from CDGS patients and normal controls. While there was a decrease in the glycosylation of serum glycoproteins of affected individuals, differences were not seen in either monosaccharide composition or oligosaccharide structures. The lectin-binding profiles of glycopeptides from [2-3H]-mannose-labeled fibroblasts were likewise indistinguishable. However, the incorporation of [2-3H]mannose into both glycoproteins and the dolichol-linked oligosaccharide precursor was significantly reduced. Thus, at least in some patients, CDGS is not due to a defect in processing of N-linked oligosaccharides, but rather to defective synthesis and transfer of nascent dolichol-linked oligosaccharide precursors. This abnormality could result in both a failure to glycosylate some sites on some proteins, as well as secondary abnormalities in overall glycoprotein processing and/or function. (J.
Introduction
The carbohydrate-deficient glycoprotein syndrome (CDGS)' was initially described 10 years ago (1, 2) as an inherited disor- 1 . Abbreviations used in this paper: CDGS, Carbohydrate-deficient Glycoprotein Syndrome; Con A, concanavalin A; Dol, dolichol; ER, endoplasmic reticulum; Gal, galactose; GalNAc, N-acetyl-galactosamine; GlcNAc, N-acetyl-glucosamine; HPAE, HPLC anion exchange chromatography with pulsed amperometric detection; LLO, lipid-linked oligosaccharide; Man, mannose; PNGase F, peptide-N4-(N-acetyl-13-glucosaminyl)asparigine amidase; Sia, sialic acid; TBA, thiobarbituric acid assay; TFA, trifluoroacetic acid. der affecting multiple organ systems including the central and peripheral nervous systems, liver, bone, adipose tissue, and genital organs (1) (2) (3) (4) (5) (6) (7) (8) (9) . Within the first few months of life, affected children present with neurological abnormalities, and their development is marked by variable but often severe psychomotor retardation, lower motor neuron dysfunction, abnormal facies, skeletal anomalies, variable hepatomegaly, and other clinical symptoms and signs. Since its initial description, the syndrome has been reported in populations from around the world, and the existence of distinct subtypes based on the severity of clinical symptoms has been suggested (10) (11) (12) (13) (14) . A characteristic biochemical abnormality of this syndrome was discovered serendipitously in the isoelectric focusing of serum transferrin (1) (2) (3) 15) , a test originally devised to screen for alcohol abuse in normal adults (16) . A consistent cathodal migration of serum transferrin was noted, and attributed to a reduction in the number of sialic acid (Sia) residues from a normal of four to five, to predominantly two, giving rise to the initial name "disialotransferrin development deficiency syndrome" (3) . Compositional studies indicated that, in addition to sialic acid, serum transferrin from affected individuals was deficient in other monosaccharides characteristic of N-linked glycans including galactose (Gal) and N-acetyl-glucosamine (GlcNAc) (3, 15) . Similar deficiencies were also reported in other serum proteins, in addition to serum transferrin (2) .
The typical side chains ("antennae") of complex-type Nlinked oligosaccharides on most normal human serum glycoproteins have the following sequence:
Sia a2-(3 or 6)Gal,61-(3 or 4)GlcNAc61-(2,4, or 6)ManalThese antennae arise from the processing (remodeling) of mannose (Man)-containing structures, and are therefore the net product of multiple exoglycosidases and glycosyltransferases (17, 18) . Thus, it was first suggested that the defect in CDGS arose from a deficiency of one or more of these processing enzymes, leading to truncated oligosaccharide structures on glycoproteins. Based on a partial decrease in total GlcNAc transferase activity in serum (2, 15) , abnormalities were postulated of one or more of the specific GlcNAc transferases responsible for the initial extension of the antennae of N-linked oligosaccharides. However, at least one previously known human defect in GlcNAc transferase activity gives rise to a completely different clinical syndrome, that of Hereditary Erythrocytic Multinuclearity with Positive Acidified Serum test (HEMPAS) (19) . Also, one report on transferrin isolated from a patient with CDGS indicated a decrease in Man content as well (10) , making the situation even less clear. Finally, two recent reports indicate that the N-linked glycans on CDGS serum transferrin are completely normal in structure, but are simply reduced in number (20) (21) (22) (23) . These authors therefore suggest a completely different defect, one of failure of attachment of one of the two N-linked oligosaccharides normally found on serum transferrin. While a specific biochemical defect was not identified, possible explanations discussed included an oligosaccharyltransferase deficiency, or a defect in the biosynthesis of the lipid-linked oligosaccharide (LLO) precursor of N-linked oligosaccharides (20, 21) .
The compositional analyses reported in the original studies were actually composite data, obtained using a variety of different colorimetric and enzymatic methods for measurement of individual monosaccharides. While this approach can yield useful information, it may be prone to error. Regardless, the global abnormality reported in total serum proteins suggest that the patients do indeed have a basic defect involving the biosynthesis of N-linked oligosaccharides (2) . Based on this assumption, we reexamined the matter using several different approaches. Focusing on N-linked oligosaccharides, an initial series of experiments were directed towards identifying a defect in the processing of N-linked oligosaccharides, presuming that the defect(s) occurred after the transfer of the high-mannose oligosaccharide from dolichol to the nascent protein chain in the endoplasmic reticulum (ER). Surprisingly, these experiments failed to show a specific processing defect. However, further experiments suggested a defect in the synthesis of the lipid-linked precursor itself, with reduced levels of [2-3H] Man incorporation into both the LLO precursor and nascent glycoproteins. As protein synthesis itself is not affected, the net result is a relative underglycosylation of glycoproteins in the CDGS samples relative to controls. In some but not all experiments, the LLO of CDGS patients was of an abnormally small size, as well. Thus, in the CDGS cases examined here, the data indicate a biosynthetic defect in the assembly of the LLO precursor. (24) .
Methods
Patients. Two sisters were diagnosed with CDGS on the basis of their clinical presentation including low birth weight, poor feeding, hypotonia, ataxia, strabismus, hepatomegaly, seizures, autistic-like behavior, characteristic fat pads, and a cathodal shift of serum transferrin in isoelectric focusing. Based upon the severity and extent of the symptoms, these patients fall into the Type I classification of Jaeken (9, 14) .
Preparation of glycopeptides from serum proteins. Serum samples (480 ul), from the two CDGS patients and two age-and sex-matched controls, were adjusted to pH 8.3 with 60 jil of 3 M Tris-Cl, pH 8.3 followed by 15 pd of Proteinase K (20 mg/ml). After 16 h at 37°C, an equal aliquot of Proteinase K was added and then digested for 36 h. Analysis by SDS-PAGE demonstrated complete digestion of serum proteins. Samples were delipidated by mixing with 1.6 ml of methanol, 0.8 ml of chloroform, and 0.52 ml of 0.2 M KCl. After vortexing and centrifuging, the upper (aqueous) layer was recovered, and the lower layer extracted twice with prepared upper phase. The combined upper phases were dried, resuspended in water, and further delipidated by passage through a reverse phase cartridge (Sepak C18 cartridge, Millipore Corp., Marlborough, MA) and elution with water. Finally, the samples were desalted over a 15-ml BioRad P-2 column run in 10 mM ammonium formate and lyophilized. (28) . The amount of /6-Gal exposed at the nonreducing termini of the glycoconjugates was determined by digestion with bovine testicular ,6-galactosidase. After digestion, the samples were mixed with 200 pmol of 2-deoxyglucose (as an internal standard), desalted on Amberlite mixed bed ion exchange resin (Sigma Chem. Co.) and analyzed by HPAE-PAD. In parallel, identical samples were treated with sialidase prior to /3-galactosidase digestion, and the difference in Gal release was used to calculate the amount of Sia-capped /3-Gal.
Examination of serum N-and 0-linked oligosaccharides by HPAE-PAD. Serum samples were dialyzed extensively against 0.15 M NaCl and 2 mM EDTA, pH 7.0, before hydrazinolysis. Samples from controls and patients (containing 1 mg protein) were submitted to hydrazinolysis using a hydrazinolysis instrument (Glycoprep 1000; Oxford GlycoSystems, Inc., Rosedale, NY) Under the settings used (95°C for 4 h), the instrument gives good recovery of released N-and O-linked chains that have also been re-N-acetylated. Alternatively, N-linked oligosaccharides were released and purified from serum glycoproteins by digestion with PNGase F as described (26) .
Released oligosaccharides were analyzed by HPAE-PAD using a GlycoStation equipped with a Carbo-Pac PA-1 column (Dionex Corp.). A linear gradient of sodium acetate (20-250 mM) with a constant concentration of sodium hydroxide (100 mM) capable of separating 0-and N-linked oligosaccharides was used (27) .
Cell lines. Primary fibroblast cultures, established from punch biopsies of skin, were grown in a-MEM supplemented with 10% FCS, and serially passaged by trypsinization. Control fibroblasts included normal pediatric samples, which were limited in availability, as well as pediatric samples from patients suffering from disorders known not to express the transferrin abnormality diagnostic of CDGS (including a seizure disorder and an unclassified movement disorder associated with ataxia and tremor). Additionally Lectin affinity chromatography. [2-3H] Man-labeled glycopeptides were analyzed on a 2-ml column of Con A Sepharose as previously described (29) . L4-PHA Sepharose and E4-PHA Sepharose affinity chromatography was carried out as described (29) , except that a [14C]_ ManNAc internal marker was added to accurately mark the position of unretained molecules.
Determination of incorporation of [2-3H] Man into cultured fibroblasts relative to total protein synthesis. Fibroblasts were labeled with [2-3H] Man (20 pCi/ml) and [35S]Methionine (2 pCi/ml) for 60 min in DMEM containing 0.1 mg/ml glucose. After removal of the radioactive medium, cells were quickly washed twice with ice-cold PBS, and harvested by trypsinization. Cell pellets were surface washed with 1 ml water, sonicated, and solubilized in 0.1% SDS. A portion of the material was used for protein determination, and the remainder was precipitated with 10% TCA, resolubilized, mixed with scintillation fluid, and counted. Incorporation was normalized to protein content.
Isolation and characterization of the LLO precursor from fibroblasts. Fibroblasts grown in glass petri dishes were labeled with [2- 3H]Man (100 ,uCi/ml) in DMEM, 0.1 mg/ml glucose, for 30 min. After removing the radioactive medium, cells were quickly washed twice with ice-cold PBS, and then 5 ml of CHCl13MeOH (2:1, vol/vol) was added at 0C (30) . Cells were scraped, extracted twice with the same solvent, and then dried in a stream of nitrogen. A small amount of water was added to the dried cells, which were then sonicated and centrifuged. The pellet was washed several times with water to remove the free label, and then LLO were extracted with CHCl3MeOH/H20 (10:10:3 vol/vol/vol). Oligosaccharides were released from the lipid by mild acid hydrolysis (30) . After extraction of the LLO, the residual pellet was solubilized in 0.1% SDS and subjected to PNGase F digestion to obtain the oligosaccharides from proteins as described (26) . The released free oligosaccharides obtained were reduced with sodium borohydride in sodium borate buffer, pH 9.8 (31) . After evaporation of methyl borate, the labeled products were desalted on Amberlite MB3 mixed bed resin and analyzed by HPLC on an AX5 column using a linear gradient of water in acetonitrile (31) at a flow rate of 1 mL/rimin using a 60-min program.
Results
Carbohydrate compositional analyses of total serum proteins. Prior work by others (2, 3, 15) has suggested that the biochemical abnormality of CDGS is a defect in the processing of Nlinked oligosaccharides of serum glycoproteins, leading to decreased molar amounts of sialic acid, Gal, and GlcNAc, but not Man. These monosaccharides are found on the outer antennae of N-linked oligosaccharides. These analyses were performed with a combination of colorometric and enzymatic assays to quantitate individual monosaccharides, assays that are known to be susceptible to variable interference. Therefore, we sought to repeat these analyses utilizing HPAE-PAD, a technique that permits the direct quantitation of all possible monosaccharides (except sialic acid) in a single chromatographic run. Moreover, the sensitivity of this approach requires only -10 ILI serum per analysis. For these analyses, glycopeptides were first generated from serum glycoproteins from two children with CDGS and from two age-and sex-matched controls. By the method employed, the resulting samples would contain most of the serum N-and 0-linked carbohydrate structures but would be substantially free of glycolipids. The total hexose content of these samples was determined by the phenol sulfuric acid assay (utilizing Man as a standard), and equivalent amounts of hexose subjected to total acid hydrolysis followed by quantitation of the released sugars by HPAE-PAD. No major differences are seen in the monosaccharide compositions other than a slight increase in GalNAc content (Table I) . However, GalNAc is not a major constituent of serum protein N-linked oligosaccharides, being a more common constituent of 0-linked chains and glycolipids. More relevant to N-linked oligosaccharide structure, the molar ratios of Gal/Man and GlcNAc/Man show no significant differences between patients and controls (Table I) . Altered ratios of these sugars were reported in some of the earlier studies (3, 15) . In contrast to these negative results, the total hexose content of the patient samples show a significant reduction relative to the amount of protein (Table I) , although the albumin and total protein contents of the samples were within normal limits (Table I , and data not shown).
Amounts ofsialic acids and ,/-Gal residues in serum glyco- (Table II) .
Analysis oftotal serum N-linked oligosaccharides. The compositional analyses reported above could still miss subtle changes in the overall structure of the N-linked oligosaccharides, especially if they selectively affected only certain subsets Fig.  3 . In particular, there appear to be lower levels of the peaks corresponding to the tri-and tetra-antennary chains (peaks 12-14, as labeled in Fig. 1 ). However, these are minor components even in the normal serum samples, and the differences are not consistent between the samples. In the hydrazinolysis-released material, the patients' samples appear to contain slightly higher levels of the early eluting peak 4 ( Figs. 1 and 3 a-methyl mannoside) (29) . The last group contains biosynthetic precursors of the other two. Thus, any major defect in the processing of N-linked oligosaccharides from high-mannose type to complex type should have a gross effect on the Con A elution profiles; however, none are seen (Table III) . In one sample, further analysis was done using L4-PHA and E4-PHA Sepharose chromatography, to uncover certain changes in the branching of N-linked oligosaccharides (29) . Again, no significant differences were seen. To ensure that the analysis was confined to N-linked oligosaccharides alone, the labeled oligosaccharides from one pair of normal and CDGS fibroblasts were released and isolated from total cellular glycoproteins using PNGase F. Analysis of these structures by Con A affinity chromatography again showed no obvious differences (data not shown). In view of these predominantly negative results, complete studies by lectin affinity chromatography were not done. Taken together, the data indicate that, as in the case of serum glycoproteins (synthesized primarily by hepatocytes and hematopoietic cells), there are no major changes in the N-linked oligosaccharides synthesized by cultured human fibroblasts. Abnormalities in the synthesis ofLLO. The data above indicate that while minor differences are present, no substantial structural abnormality is seen in the N-linked oligosaccharides of the CDGS patients when compared with normal individuals. However, they do not address events that take place in the earliest stages of the N-linked oligosaccharide biosynthetic pathway (i.e., the formation of the LLO precursor and its en bloc transfer to newly synthesized proteins) (17, 18) . To explore these steps, we labeled the LLO metabolically in cultured fibroblasts using a short pulse label (60 min) of [2-3H] (Table IV) . Thus, the rate of transfer of oligosaccharide from the lipid precursor to protein is not likely to be the primary defect in CDGS; rather, some earlier step involved in the biosynthesis of the LLO is implicated. An alternative explanation for the decreased levels of [2-3H]Man incorporated into LLO and protein presented in Tables IV and V is that the size of the precursor is smaller, resulting in the same amount of LLO but with fewer Man residues and thus less 3H label. To examine this possibility, cells were labeled with [2-3H] Man as before, the LLO was extracted, and the oligosaccharides were released from the lipid by mild acid hydrolysis. In parallel, the N-linked oligosaccharides were released from proteins by digestion with PNGase F. These two populations of oligosaccharides were fractionated by size, by chromatography on an AX5 column (31) . Normal cells make a heterogeneous array of oligosaccharides in the LLO and protein fraction. Their sizes correspond to those with five to nine Man residues, with the greatest portion having nine (data not shown). In contrast, the oligosaccharides from CDGS cells are much more variable in size. In approximately half of the experiments, the LLO and protein oligosaccharides contain a higher proportion of structures containing five or fewer Man residues, while in the remaining experiments, the structures are similar in size to those from normal fibroblasts. The cause of this variability could not be traced to cell density, labeling conditions, or passage number, and is currently under investigation. Smaller oligosaccharides would contain fewer [2-3H] Man residues, and thus have a lower amount of radioactivity than normally sized structures. However, even when the decrease in incorporation is normalized for the difference in size of the LLO (three separate experiments), CDGS patients make only 30-35% of the amount of LLO found in normal cells. Thus, the decreased protein glycosylation in CDGS does not require an altered LLO structure; rather, it is a reflection of a reduced amount of LLO itself. Once transferred to proteins, these truncated oligosaccharides can be processed normally, and thus may not be apparent on the fully processed glycoproteins. No evidence for abnormally processed structures was found in our studies (Figs. 1-3 ) nor in those of others (21) .
Discussion
The original biochemical description of CDGS focused on abnormal isoforms of serum transferrin. Five different charge isoforms can be identified by isoelectric focusing, which represent polypeptide chains containing from zero to four sialic acid residues (3, 15) . Transferrin is known to contain two N-linked glycosylation sites, consisting of 80% biantennary structures and 20% tri-and tetraantennary structures (33, 34 (20, 21) . However, a subsequent study indicates that the defect is not the synthesis of dolichyl phosphate or N-acetylglucosaminyl-pyrophosphoryl-dolichol (35) . Utilizing several different approaches, we have explored the biochemical basis of CDGS in two patients. Contrary to prior reports, we find no differences in the composition of monosaccharides in total serum glycoproteins in this disease. The disparity may be because the prior studies utilized enzymatic and colorimetric assays, whereas the current work used direct chromatographic determination by HPAE-PAD analysis. Based upon the well known structure of the typical antennae of Nlinked oligosaccharides and the invariant nature of the core structure (Man3GlcNAc2), the constant ratios of monosaccharide composition indicate that there is no major change in the overall extent of processing of the N-linked oligosaccharides found on serum glycoproteins. Profiling of the total N-linked oligosaccharides by HPAE-PAD confirms this conclusion. Although we did not identify the structure of each of the oligosaccharide peaks, the overall similarity in the profile indicates that only minor differences are present. In fact, the only obvious difference involves oligosaccharides released by hydrazinolysis but not by PNGase F, which represent O-linked or possibly PNGase F-resistant structures. A difference in O-linked structures would also fit with the increase in content of GalNAc, a monosaccharide more commonly found in O-linked oligosaccharide structures. However, such abnormalities could still be secondary due to a primary failure in N-linked glycosylation.
Since the majority of serum glycoproteins are produced either by hepatocytes or hematopoietic cells, the molecules we first studied represent the final biosynthetic products of these cell types. For another perspective, we also examined skin fibroblasts metabolically labeled with [2- (37) (38) (39) (40) . The enzymatic defects in these cell lines include reduced levels of polyprenol reductase activity (required for the biosynthesis of dolichol), and of mannosylphosphoryldolichol synthase (required for the biosynthesis of Man-P-Dol; see 37, 39, 45, 46) . The abnormal LLO structure in the last case has been determined to be Glc3Man5GlcNAc2-P-P-Dol (36, 37) , again in contrast to the heterogeneous sizes of the LLO seen here. Saccharomyces cerevisiae sec59 cells, which are deficient in dolichol kinase activity (47) , show reduced levels of Man incorporation into nascent proteins, as seen with the CDGS samples. However, in these mutants, the oligosaccharides are consistently smaller than in normal cells (48) , again unlike the situation here. As a further complexity, recent studies have indicated that dolichol biosynthesis is tightly controlled by cAMP levels in some cell lines (49) sugar nucleotides, which could secondarily affect the structure and/or amount of the LLO (see Fig. 4 ). (53) , and suggests a plausible hypothesis for the hypogonadism reported in some cases of CDGS (7, 9, 54).
Based on variabilities in clinical phenotype of CDGS patients, three subtypes have recently been suggested, and the proposal that these may correspond to abnormalities at widely differing steps in the N-linked oligosaccharide biosynthetic pathway has been extended (12) . While this may explain both the clinical and biochemical heterogeneity of this disorder, as well as some of the conflicting reports in the literature, sufficient data have yet to be presented to support this model. The 
